<DOC>
	<DOCNO>NCT01289626</DOCNO>
	<brief_summary>The research question primary aim determine lanthanum carbonate effective treating calciphylaxis measurement complete partial remission skin lesion . Secondary endpoint measure determine lanthanum carbonate lower calcium-phosphorus product level , intact PTH mortality . Albumin level measure marker nutritional status inflammation .</brief_summary>
	<brief_title>Efficacy Lanthanum Carbonate Calciphylaxis</brief_title>
	<detailed_description>Calciphylaxis calcific uremic arteriolopathy infrequently occur although debilitate vasculopathy see primarily patient end stage renal disease ( ESRD ) almost always affect skin . It prevalence rate ~4 % long term hemodialysis patient , 1-year survival 45 % 8-fold risk death compare general dialysis population . ( Surgery 1997 ; 122:1083-1089 , Kidney Int 2001 ; 60:324-332 ) . Despite described literature 100 year , proven effective therapy . Lanthanum carbonate ( FOSRENOL® ) potent non-aluminum , non-calcium phosphate binder approve use reduce serum phosphate level patient end stage renal disease . Since propose etiologic mechanism injury vascular calcification calciphylaxis predominantly hyperphosphatemia , elevate serum PTH , hypercalcemia , FOSRENOL® would ideal pharmacologic agent utilize extremely enigmatic disease ( Dermatol Clin . 2008 Oct ; 26 ( 4 ) :557-68 ) . Furthermore , recent case report demonstrate significant improvement laboratory parameter calciphylaxis skin lesion use FOSRENOL® ( WMJ . 2008 Nov ; 107 ( 7 ) :335-8 ) . The primary hypothesis since calciphylaxis represent ultimate sequela metastatic vascular calcification predominantly involve hyperphosphatemia , elevate serum PTH , hypercalcemia , FOSRENOL® efficacious treatment .</detailed_description>
	<mesh_term>Calciphylaxis</mesh_term>
	<criteria>Participants sign witness informed consent . ii Participants great equal 18 year age iii Chronic renal failure receive hemodialysis peritoneal dialysis iv A diagnosis calciphylaxis proven skin biopsy initial dermatology visit within previous 5 year v Serum phosphorus &gt; 4.5 mg/dL Participants able understand provide write informed consent ii The research team deem participant may able follow study protocol . iii Nondependent HD patient receive dialysis acute kidney injury ; iv Pregnant dialysis patient v Active gastrointestinal obstruction bleed vi Active inflammatory bowel disease vii Acute arteriovenous graft occlusion viii Known hypersensitivity FOSRENOL®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Calciphylaxis , dialysis</keyword>
</DOC>